PHARMACOKINETICS OF MIBAVADEMAB (MIBA) IN HEALTHY PARTICIPANTS: RESULTS FROM A RANDOMIZED, PHASE 1, TWO-PART, FIRST-IN-HUMAN STUDY

被引：0

作者：

Mendell, J. ^{[1
]}

Gewitz, A. ^{[1
]}

Wang, Y. ^{[1
]}

Harnisch, L. ^{[1
]}

Olenchock, B. ^{[1
]}

Pan, H. ^{[1
]}

Podgrabinska, S. ^{[1
]}

Zheng, W. ^{[1
]}

Zhao, A. ^{[1
]}

Vanhoutte, F. ^{[2
]}

Davis, J. ^{[1
]}

机构：

[1] Regeneron Pharmaceut, Tarrytown, NY USA

[2] SGS Clin Pharmacol Unit, Antwerp, Belgium

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2023年 / 113卷

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

PII-074

引用

页码：S67 / S68

页数：2

共 50 条

[21] Two-Part Phase 1 Multiple-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of TRV734 in Healthy Adults
Ramos, Kimberly A.
James, Ian E.
Skobieranda, Franck
Soergel, David G.
Ruff, Dennis
Fossler, Michael J.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (01): : 51 - 62
[22] A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation
Daniel, Weston L. L.
Lorch, Ulrike
Mix, Scott
Bexon, Alice S. S.
FRONTIERS IN IMMUNOLOGY, 2022, 13
[23] Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese Participants
Cheung, Tommy Tsang
Mai, Tu H.
Chia, Yen Lin
Yap, Desmond Y. H.
Lee, Chi-Ho
Chen, Cecil Chi-Keung
Huang, Ying
Jin, Yuwen
Johnston, James
Werkstroem, Viktoria
Yao, Yuhui
Ge, Xiaoyun
Zheng, Wenying
DRUG DESIGN DEVELOPMENT AND THERAPY, 2023, 17 : 209 - 218
[24] First-in-Human Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAR443820, a Central Nervous System Penetrant RIPK1 Inhibitor in Healthy Participants
Hincelin-Mery, Agnes
Lewanczyk, Pascale
Cantalloube, Cathy
Nicolas, Xavier
Benamor, Myriam
Pomponio, Robert
Krupka, Emmanuel
Ofengeim, Dimitry
Eastenson, Amy
Xiong, Li
Atassi, Nazem
NEUROLOGY, 2023, 100 (17)
[25] Safety, Tolerability, and Pharmacokinetics of a Novel Anti-Influenza Agent ZX-7101A Tablets in Healthy Chinese Participants: A First-in-Human Phase I Clinical Study
Wu, Junzhen
Wei, Qiong
Jin, Yi
Cao, Guoying
Yu, Jicheng
Wu, Xiaojie
Yang, Xinyi
Li, Yilin
Liu, Mei
Qin, Xiaoli
Ai, Jingwen
Wang, Yin
Zhang, Wenhong
Zhang, Jing
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2025, 65 (01)
[26] Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study
Carla Biesdorf
Xiaowen Guan
Satya R. Siddani
David Hoffman
Nils Boehm
Bruno C. Medeiros
Toshihiko Doi
Maja de Jonge
Drew Rasco
Rajeev M. Menon
Akshanth R. Polepally
Cancer Chemotherapy and Pharmacology, 2024, 93 : 329 - 339
[27] Pharmacokinetics and immunogenicity of eftozanermin alfa in subjects with previously-treated solid tumors or hematologic malignancies: results from a phase 1 first-in-human study
Biesdorf, Carla
Guan, Xiaowen
Siddani, Satya R.
Hoffman, David
Boehm, Nils
Medeiros, Bruno C.
Doi, Toshihiko
de Jonge, Maja
Rasco, Drew
Menon, Rajeev M.
Polepally, Akshanth R.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 93 (04) : 329 - 339
[28] Pregabalin pharmacokinetics and safety in healthy volunteers: Results from two Phase 1 studies
Bockbrader, HN
Hunt, T
Strand, J
Posvar, E
Sedman, A
NEUROLOGY, 2000, 54 (07) : A421 - A421
[29] Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
Tadao Akizawa
Ryutaro Shimazaki
Masanari Shiramoto
Masafumi Fukagawa
Clinical Drug Investigation, 2018, 38 : 945 - 954
[30] Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
Akizawa, Tadao
Shimazaki, Ryutaro
Shiramoto, Masanari
Fukagawa, Masafumi
CLINICAL DRUG INVESTIGATION, 2018, 38 (10) : 945 - 954

← 1 2 3 4 5 →